Ionis Q2 adjusted operating loss narrows
IONS•Outlook
- Company expects full-year 2026 TRYNGOLZA product sales of $100 million to $110 million
- Ionis expects full-year 2026 DAWNZERA product sales of $110 million to $120 million
- Company says it remains on track to achieve 2026 financial guidance
Key Q2 figures
| Metric | Actual | Consensus Estimate |
|---|---|---|
| Q2 Net Loss | $115 mln | |
| Q2 Adjusted Operating Income | -$57 mln | -$178.43 mln (15 Analysts) |
| Q2 Adjusted Operating Expenses | $325 mln | |
| Q2 Operating Expenses | $370 mln | |
| Q2 Operating Income | -$102 mln |
Quarterly results and drivers
- RNA medicines developer's Q2 adjusted operating loss narrows
- Q2 commercial revenue rose 15% year over year, driven by DAWNZERA product sales
- Higher Q2 operating expenses were due to commercialization and launch investments
Ionis said early launch momentum for TRYNGOLZA in severe hypertriglyceridemia and strong DAWNZERA sales drove commercial revenue growth.
Higher operating expenses were mainly due to investments in commercialization efforts for TRYNGOLZA, DAWNZERA, and launch preparations for zilganersen.
